瑞舒伐他汀与阿托伐他汀治疗冠心病的效果及安全性探讨

Effect and safety of rosuvastatin and atorvastatin in the treatment of coronary heart disease

目的 分析瑞舒伐他汀与阿托伐他汀治疗冠心病患者的效果及安全性。方法 100例冠心病患者,随机分为对照组和研究组,各50例。对照组患者给予阿托伐他汀治疗,研究组给予瑞舒伐他汀。比较两组患者治疗前后纽约心脏病协会(NYHA)分级、血脂监测指标[总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)]、动脉粥样硬化相关指标[颈动脉内膜中层厚度(IMT)、超敏C反应蛋白、胱抑素C]及治疗效果、不良反应发生情况。结果 治疗后,研究组TC(4.34±0.14)mmol/L、LDL-C(2.73±0.21)mmol/L、TG(1.54±0.51)mmol/L及NYHA分级(1.12±0.15)级均低于对照组的(5.67±0.14)mmol/L、(3.81±0.65)mmol/L、(2.01±0.65)mmol/L、(2.74±0.22)级,HDL-C(1.85±0.34)mmol/L高于对照组的(1.54±0.42)mmol/L,差异具有统计学意义(P<0.05)。治疗后,研究组IMT(0.91±0.12)mm小于对照组的(1.47±0.35)mm,超敏C反应蛋白(4.56±1.34)mg/L、胱抑素C(1.53±0.15)mg/L均低于对照组的(8.51±1.89)、(1.71±0.22)mg/L,差异具有统计学意义(P<0.05)。研究组总有效率96.00%高于对照组的80.00%,差异具有统计学意义(P<0.05)。研究组不良反应发生率2.00%低于对照组的14.00%,差异具有统计学意义(P<0.05)。结论 瑞舒伐他汀治疗冠心病的临床效果优于阿托伐他汀,可改善患者心功能,调节血脂,逆转动脉粥样硬化,安全性更高,值得推广。

Objective To analyze the effect and safety of rosuvastatin and atorvastatin in the treatment of coronary heart disease.Methods A total of 100 patients with coronary heart disease were randomly divided into control group and research group,with 50 cases in each group.The control group was treated with atorvastatin,and the research group was treated with rosuvastatin.Both groups were compared in terms of New York Heart Association(NYHA)grading,blood lipid monitoring indexes[total cholesterol(TC),low-density lipoprotein cholesterol(LDL-C),triglyceride(TG),high-density lipoprotein cholesterol(HDL-C)],atherosclerosis-related indicators[carotid intima-media thickness(IMT),high-sensitivity C-reactive protein,cystatin C],therapeutic effect,and occurrence of adverse reactions.Results After treatment,the TC(4.34±0.14)mmol/L,LDL-C(2.73±0.21)mmol/L,TG(1.54±0.51)mmol/L and NYHA grading(1.12±0.15)grades in the research group were lower than(5.67±0.14)mmol/L,(3.81±0.65)mmol/L,(2.01±0.65)mmol/L,and(2.74±0.22)grades in the control group;the HDL-C(1.85±0.34)mmol/L in the research group was higher than(1.54±0.42)mmol/L in the control group;the differences were all statistically significant(P<0.05).After treatment,the IMT(0.91±0.12)mm of the research group was less than(1.47±0.35)mm of the control group;the high-sensitivity C-reactive protein(4.56±1.34)mg/L and cystatin C(1.53±0.15)mg/L of the research group were lower than(8.51±1.89)and(1.71±0.22)mg/L of the control group;the differences were all statistically significant(P<0.05).The total effective rate 96.00%of the research group was higher than 80.00%of the control group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions 2.00%in the research group was lower than 14.00%in the control group,and the difference was statistically significant(P<0.05).Conclusion Rosuvastatin has better clinical effect in the treatment of coronary heart disease than that of atorvastatin,which can improve heart function,regulate blood lipids,and reverse atherosclerosis with high safety,and is worthy of promotion.